What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Disease
- Surgery
William J. Sandborn mainly focuses on Internal medicine, Gastroenterology, Surgery, Crohn's disease and Ulcerative colitis.
His Placebo research extends to Internal medicine, which is thematically connected.
His study looks at the intersection of Gastroenterology and topics like C-reactive protein with Calprotectin.
The Surgery study combines topics in areas such as Vedolizumab, Clinical trial, Incidence and Azathioprine.
As part of one scientific family, William J. Sandborn deals mainly with the area of Crohn's disease, narrowing it down to issues related to the Intensive care medicine, and often Physical therapy.
His work carried out in the field of Ulcerative colitis brings together such families of science as Primary sclerosing cholangitis and Colitis.
His most cited work include:
- Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis (2790 citations)
- Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease (2157 citations)
- Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. (1681 citations)
What are the main themes of his work throughout his whole career to date?
His scientific interests lie mostly in Internal medicine, Gastroenterology, Ulcerative colitis, Crohn's disease and Inflammatory bowel disease.
His study in Internal medicine is interdisciplinary in nature, drawing from both Placebo and Surgery.
His Gastroenterology research includes themes of Adverse effect, Maintenance therapy, Clinical endpoint, Azathioprine and C-reactive protein.
His Ulcerative colitis research is multidisciplinary, relying on both Tofacitinib, Clinical trial and Colitis.
His studies in Crohn's disease integrate themes in fields like Adalimumab, Certolizumab pegol, Ustekinumab and Intensive care medicine.
His Inflammatory bowel disease research includes themes of Immunology and Pharmacology.
He most often published in these fields:
- Internal medicine (74.60%)
- Gastroenterology (49.14%)
- Ulcerative colitis (40.39%)
What were the highlights of his more recent work (between 2017-2021)?
- Internal medicine (74.60%)
- Ulcerative colitis (40.39%)
- Gastroenterology (49.14%)
In recent papers he was focusing on the following fields of study:
Internal medicine, Ulcerative colitis, Gastroenterology, Crohn's disease and Inflammatory bowel disease are his primary areas of study.
Clinical endpoint is closely connected to Placebo in his research, which is encompassed under the umbrella topic of Internal medicine.
In Ulcerative colitis, he works on issues like Infliximab, which are connected to Adalimumab.
His research investigates the connection between Gastroenterology and topics such as Calprotectin that intersect with issues in Feces.
His Crohn's disease study combines topics from a wide range of disciplines, such as Hazard ratio, Moderate to severe and Intensive care medicine.
His study in Inflammatory bowel disease is interdisciplinary in nature, drawing from both Immunology and Cohort study.
Between 2017 and 2021, his most popular works were:
- Treatment and prevention of pouchitis after ileal pouch‐anal anastomosis for chronic ulcerative colitis (169 citations)
- Management of Patients With Crohn's Disease and Ulcerative Colitis During the Coronavirus Disease-2019 Pandemic: Results of an International Meeting. (94 citations)
- Safety of Tofacitinib for Treatment of Ulcerative Colitis, Based on 4.4 Years of Data From Global Clinical Trials. (84 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Disease
- Cancer
William J. Sandborn mainly focuses on Internal medicine, Ulcerative colitis, Crohn's disease, Inflammatory bowel disease and Gastroenterology.
His Internal medicine study frequently draws connections between adjacent fields such as Placebo.
His Ulcerative colitis research is multidisciplinary, incorporating elements of Therapeutic drug monitoring, Infliximab, Tofacitinib and Maintenance therapy.
His Crohn's disease research integrates issues from Surgery, Endoscopy and C-reactive protein.
William J. Sandborn combines subjects such as Odds ratio, Relative risk, Cohort study and Immunology with his study of Inflammatory bowel disease.
His Gastroenterology research incorporates themes from Pharmacokinetics, Phases of clinical research, Confidence interval, Azathioprine and Induction therapy.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
